- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06896656
Improving Social Connectedness Through Digital Health to Enhance Recovery From OUD Among the Justice Involved Population (STAR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18+ years of age
- history of being prescribed medication for opioid use disorder (MOUD) while in jail or prison
- most recently released from prison with the past two years
- self-reported recovery for an Opioid Use Disorder (OUD)
- able to understand and speak English and to provide written and verbal consent
- anticipated discharge from jail/prison within 3 months if currently incarcerated
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MPS App
This is the experimental arm.
Participants assigned to this arm will receive access to the Marigold Health App (MPS) intervention.
N = 60 participants will be assigned to this arm.
|
The MPS App is a secure platform that allows text-based peer support for individuals in recovery from OUD. Participants assigned to this condition will be enrolled on a rolling basis into a peer support group on the app. All participants will receive onboarding assistance and will have access to the app for 6 months. The app will include live moderation from a certified Peer Recovery Support Specialist and trained research assistants. Moderators will begin discussions with prompts and regulate the flow of conversation with standardized text language. Moderators will be able to respond in real-time to malicious messages or other "flags" that could impact participant safety. Built in natural language processing algorithms will also detect language requiring intervention and automatically alter the moderators and on-call clinicians. |
|
Active Comparator: Enhanced Treatment as Usual
This is the active comparator arm.
Participants assigned to this arm will receive enhanced treatment as usual.
N = 30 participants will be assigned to this arm.
|
A list of online peer support and mental health resources, drawn from SAMSHA and equivalent websites, will be provided to all participants, as an enhanced adjunct to their standard recovery plans.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Social Support
Time Frame: Baseline, 1, 3, and 6 months.
|
Perceived social support will be assessed with the Multidimensional Scale of Perceived Social Support (MSPSS).
This assessment is psychometrically sound, with adequate reliability and validity, and measures perceived social support from family, friends, and significant others among adults.
Scores are averaged and range from 1 to 7, with 1 signifying the lowest level of social support and 7 signifying the highest.
|
Baseline, 1, 3, and 6 months.
|
|
Loneliness
Time Frame: Baseline, 1, 3, and 6 months.
|
Loneliness will be assessed with the 20-item UCLA Loneliness scale.
Scores range from 20 to 80, where higher scores indicate greater loneliness.
|
Baseline, 1, 3, and 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Substance Use
Time Frame: Baseline, 1, 3, and 6 months.
|
Self-reported substance use will be assessed with the Timeline Follow-Back interview and biochemically confirmed with Urine Drug Screens.
Substance use will be operationalized as the percentage of days positive for drug use (separate by drug class) in between assessments.
|
Baseline, 1, 3, and 6 months.
|
|
Engagement in Medications for Opioid Use Disorder (MOUD)
Time Frame: Baseline, 1, 3, and 6 months.
|
Self-reported engagement in MOUD will be assessed with a Timeline Follow-Back interview and biochemically confirmed with Urine Drug Screens.
Engagement in MOUD will be operationalized as the percentage of days positive for MOUD administration in between assessments.
|
Baseline, 1, 3, and 6 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographics
Time Frame: Baseline
|
Using the PhenX toolkit, basic demographic data and social determinants of health will be collected.
In addition, prior and current history with the criminal justice system will be assessed with the Adult Incarceration Module of the National Survey on Drug Use and Health (NSDUH) 2014 Questionnaire.
|
Baseline
|
|
Treatment Received
Time Frame: Baseline, 1, 3, and 6 months.
|
The Treatment Services Review will be administered to assess receipt of case management, psychiatric, peer recovery coaching, and other treatment services, including utilization of MOUD.
At follow-up interviews, participants will be asked about the services received since the previous interview.
|
Baseline, 1, 3, and 6 months.
|
|
Quality of Life
Time Frame: Baseline, 1, 3, and 6 months.
|
The Quality of Life Enjoyment and Satisfaction Questionnaire Short Form, a 16-item questionnaire with sound psychometric properties, will be administered to assess quality of life.
Scores range from 0 to 100, with higher scores indicating greater enjoyment and satisfaction.
|
Baseline, 1, 3, and 6 months.
|
|
Wellbeing
Time Frame: Baseline, 1, 3, and 6 months.
|
The World Health Organization-Five Well-Being Index (WHO-5) will be administered to assess wellbeing.
This 5-item questionnaire is a widely used and valid tool for assessing wellbeing.
Scores range from 0 to 100, with 0 representing the worst possible wellbeing and 100 representing the best possible wellbeing.
|
Baseline, 1, 3, and 6 months.
|
|
Depressive Symptoms
Time Frame: Baseline, 1, 3, and 6 months.
|
Depressive symptoms will be assessed with the Patient Health Questionnaire-2 (PHQ-2).
This measure consists of 2 items with high sensitivity, specificity, and discriminant validity for diagnosing major depression.
Scores range from 0 to 6.
A score of 3 or greater indicates major depression disorder is likely.
|
Baseline, 1, 3, and 6 months.
|
|
Anxiety Symptoms
Time Frame: Baseline, 1, 3, and 6 months.
|
Anxiety symptoms will be assessed with the Generalized Anxiety Disorder 2-Item (GAD-2).
This measure consists of 2 items and has well established accuracy for identifying clinically significant anxiety symptoms and tracking treatment progress outcomes.
Scores range from 0 to 6.
A score of 3 or greater indicates a high likelihood of generalized anxiety disorder diagnosis.
|
Baseline, 1, 3, and 6 months.
|
|
Perceived Stress
Time Frame: Baseline, 1, 3, and 6 months.
|
The Perceived Stress Scale (PSS-10) will be administered to assess perceived stress in the past month.
The PSS-10 consists of 10 items and is psychometrically sound.
Scores range from 0 to 40, with 40 representing the highest possible perceived stress.
|
Baseline, 1, 3, and 6 months.
|
|
Number of Days of App Use
Time Frame: 6 months
|
The number of days participants use the Marigold Health app will be extracted from the app as indices of app engagement.
|
6 months
|
|
Number of Messages Sent in App
Time Frame: 6 months
|
The number of messages a participant sends in the Marigold Health app will be extracted from the app as an indices of app engagement.
|
6 months
|
|
System Usability Scale
Time Frame: 6 months
|
The System Usability Scale will be administered to participants in the treatment arm.
This assessment measures perceived usability of digital systems.
Scores range from 0 to 100, with 100 representing high perceived usability.
These scores will be used as indices of app satisfaction.
|
6 months
|
|
Client Satisfaction Questionnaire
Time Frame: 6 months
|
The Client Satisfaction Questionnaire will be administered to participants in the treatment arm.
This measure of intervention satisfaction consists of 8 items.
Scores range from 8 to 32, with higher scores indicting higher satisfaction.
These scores will serve as indices of app satisfaction.
|
6 months
|
|
Qualitative Exit Interview
Time Frame: 6 months
|
Qualitative exit interviews will be conducted with a subset of participants (n = 20) assigned to the treatment arm.
The interviews will be used to collect in-depth feedback about the intervention.
|
6 months
|
|
Number of Flagged Messages
Time Frame: 6 months
|
The number of messages flagged in the Marigold Health app will be extracted from the app.
This will serve as indices of safety of the app.
|
6 months
|
|
Number of Crisis Interventions
Time Frame: 6 months
|
The number of crisis interventions clinicians administer to participants using the Marigold Health app will be extracted from the app.
This will serve as indices of app safety.
|
6 months
|
|
Time Spent Onboarding App Users
Time Frame: 6 months
|
The amount of time required for research staff to onboard users to the Marigold Health app will be recorded.
This will serve as indices of intervention scalability.
|
6 months
|
|
Clinician Time Spent on Crisis Managment
Time Frame: 6 months
|
The amount of time it takes clinicians to manage emergent crises on the Marigold Health app will be recorded.
This will serve as indices of intervention scalability.
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R34DA058299 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.